Amaç: Tedavi gerektiren prematüre retinopatisi (TG-ROP) nedeni ile tedavi uygulanan hastaların erken dönem geniş açı görüntüleme cihazı floresein anjiyografi (FA) bulgularını değerlendirmektir. Gereç ve Yöntemler: Retrospektif çalışmada TG-ROP nedeni ile tedavi uygulanan 20 hastada; prematüre retinopatisi gelişimi açısından bebeğe ve anneye ait risk faktörleri, ROP hastalığının evre, yerleşim ve yaygınlığı, uygulanan tedavi yöntemi ile tedavi sonrası 3-12. haftalar arasındaki geniş açı görüntüleme cihazı FA görüntüleri değerlendirildi. Bulgular: Tüm gözlerde zon 2'de; 24 (%60) gözde evre 2, 8 (%20) gözde evre 3, 8 (%20) gözde agresif ROP olmak üzere ortalama 10,14±2,72 (6-12) saat kadranı ROP ve plus hastalık mevcuttu. Yirmi sekiz (%70) göze lazer, 12 (%30) göze intravitreal bevasizumab (İVB) enjeksiyonu uygulanmıştı. En sık görülen tedavi sonrası erken dönem geniş açı görüntüleme cihazı FA bulguları sıklık sırasına göre; 30 (%75) gözde sirkümferensiyal damar, 25 (%62,5) gözde arteriovenöz şant, 20 (%50) gözde anormal vasküler dallanma, 12 (%30) gözde hiperfloresan kapiller yumak, 10 (%25) gözde avasküler retina (AR) ve 10 (%25) gözde fokal kapiller dilatasyondu. AR, periferal kapiller yatak kaybı ve vaskülarize retinada hipoforesan lezyonlar İVB ile tedavi edilen gözlerde istatistiksel olarak anlamlı düzeyde daha sık görülürken diğer FA bulgularında fark yoktu. Sonuç: Çalışmamızda TG-ROP'ta tedavi öncesinde görülebilen anormal FA bulgularının tedavi sonrası ilk 3 aylık erken dönemde hem lazer fotokoagülasyon uygulanan hem de İVB yapılan gözlerde birbirine benzer oranlarda saptanabileceği görülmüştür. AR, periferal kapiller yatak kaybı ve vaskülarize retinada hipoforesan lezyonlar İVB ile tedavi edilen gözlerde daha sık görülürken diğer FA bulgularında fark yoktu.
Anahtar Kelimeler: Prematüre retinopatisi; sirkümferensiyal damar; arteriovenöz şant; avasküler retina
Objective: To evaluate the early wide-angle imaging device fluorescein angiography (FA) findings of patients treated for treatment requiring retinopathy of prematurity (TR-ROP). Material and Methods: In this retrospective study, in 20 patients who were treated for treatment requiring ROP, infant and maternal risk factors for ROP development, stage, zone and extent of ROP disease, treatment method and wide-angle imaging device FA images between 3-12 th weeks after treatment after treatment were evaluated. Results: All eyes had ROP and plus disease in zone 2 with a mean of 10.14±2.72 (6-12) clock hours with stage 2 in 24 (60%) eyes, stage 3 in 8 (20%) eyes and aggressive ROP in 8 (20%) eyes. Twenty-eight (70%) eyes received laser and 12 (30%) eyes received intravitreal bevacizumab injection (IVB). The most common early post-treatment wide-angle imaging device FA findings, in order of frequency, were circumsferential vessels in 30 (75%) eyes, arterio-venous shunt in 25 (62.5%) eyes, abnormal vascular branching in 20 (50%) eyes, hyperfluorescent capillary tangles in 12 (30%) eyes, avascular retina (AR) in 10 (25%) eyes and focal capillary dilatation in 10 (25%) eyes. AR, peripheral capillary bed loss and hypofluorescent lesion in the vascularized retina were statistically significantly more common in eyes treated with IVB, while there was no difference in other FA findings. Conclusion: Our study observed that abnormal FA findings that can be seen before treatment in ROP can be detected in both laser photocoagulated and intravitreal anti-VEGF-treated eyes in the first 3 months after treatment. AR, loss of peripheral capillary bed and hypofluorescent lesion in the vascularized retina were more common in eyes treated with antiVEGF, while there was no difference in other FA findings.
Keywords: Retinopathy of prematurity; circumferential vessel; arteriovenous shunt; avascular retina
- Bas AY, Demirel N, Koc E, Ulubas Isik D, Hirfanoglu İM, Tunc T; TR-ROP Study Group. Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): a prospective, multicentre study in 69 neonatal intensive care units. Br J Ophthalmol. 2018;102(12):1711-6. [Crossref] [PubMed] [PMC]
- Kim SJ, Port AD, Swan R, Campbell JP, Chan RVP, Chiang MF. Retinopathy of prematurity: a review of risk factors and their clinical significance. Surv Ophthalmol. 2018;63(5):618-37. [PubMed] [PMC]
- Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Paul Chan RV, Berrocal A, et al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021;128(10):e51-e68. [Crossref] [PubMed] [PMC]
- Kvopka M, Chan W, Lake SR, Durkin S, Taranath D. Fundus fluorescein angiography imaging of retinopathy of prematurity in infants: a review. Surv Ophthalmol. 2023;68(5):849-60. [PubMed]
- Lepore D, Molle F, Pagliara MM, Baldascino A, Angora C, Sammartino M, et al. Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity. Ophthalmology. 2011;118(1):168-75. [Crossref] [PubMed]
- Rowe LW, Belamkar A, Antman G, Hajrasouliha AR, Harris A. Vascular imaging findings in retinopathy of prematurity. Acta Ophthalmol. 2024;102(4):e452-e472. [PubMed] [PMC]
- Perente I, Eris E, Seymen Z, Cevik SG, Bekmez S. Aggressive posterior retinopathy of prematurity treated with intravitreal bevacizumab: late period fluorescein angiographic findings. Graefes Arch Clin Exp Ophthalmol. 2019;257(6):1141-6. [Crossref] [PubMed]
- Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings. Ophthalmology. 2018;125(2):218-26. [Crossref] [PubMed]
- Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014;121(11):2212-9. [Crossref] [PubMed]
- Lepore D, Ji MH, Ying GS, Orazi L, Pagliara MM, Quinn GE; FA team of the Italian ROP study Group. Early angiographic signs of retinopathy of prematurity requiring treatment. Eye (Lond). 2021;35(11):3094-101. [PubMed] [PMC]
- Hans A, Narang S, Sindhu M, Jain S, Chawla D. Fundus fluorescein angiography in retinopathy of prematurity. Eye (Lond). 2022;36(8):1604-9. [PubMed] [PMC]
- Mansukhani SA, Hutchinson AK, Neustein R, Schertzer J, Allen JC, Hubbard GB. Fluorescein angiography in retinopathy of prematurity: comparison of infants treated with bevacizumab to those with spontaneous regression. Ophthalmol Retina. 2019;3(5):436-43. [PubMed] [PMC]
- Bayramoglu SE, Sayin N. Inter-eye comparison of retinal vascular growth rate and angiographic findings following unilateral bevacizumab treatment. Eur J Ophthalmol. 2022;32(3):1430-40. [PubMed]
- Bayramoglu SE, Sayın N. Fluorescein angiography findings in treatment-naive premature infants with retinal vascular immaturity and persistent avascular retina. Semin Ophthalmol. 2022;37(6):740-8. [PubMed]
- Vural A, Ekinci DY, Onur IU, Hergünsel GO, Yiğit FU. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression. Int Ophthalmol. 2019;39(10):2267-74. [PubMed]
- Vural A, Demirayak B, Ozbas M, Onur IU, Celik G. Comparison of fluorescein angiography findings in stage 3 retinopathy of prematurity in zone II treated with or without anti-vegf. Eur J Ophthalmol. 2022;32(6):3281-8. [PubMed]
- Wood EH, Ji MH, Rao P, Lertjirachai I, Nguyen L, Sbrocca RV, et al. Management of type 2 retinopathy of prematurity or less in infants aged 45 weeks postmenstrual age or older. Ophthalmic Surg Lasers Imaging Retina. 2021;52(12):636-41. [PubMed]
.: Process List